¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"noncongestive glaucoma"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 13 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • lens-induced glaucoma
    ¼öÁ¤Ã¼³ì³»Àå
  • low-tension glaucoma
    Àú¾È¾Ð³ì³»Àå
  • neovascular glaucoma
    ½Å»ýÇ÷°ü³ì³»Àå
  • narrow-angle glaucoma
    Á¼Àº¾Õ¹æ°¢³ì³»Àå, ÇùÀü¹æ°¢³ì³»Àå
  • normal tension glaucoma
    Á¤»ó¾È¾Ð³ì³»Àå
  • open-angle glaucoma
    °³¹æ°¢³ì³»Àå
  • pigmentary glaucoma
    »ö¼Ò³ì³»Àå
  • pseudoexfoliation glaucoma
    °ÅÁþºñ´Ã³ì³»Àå
  • pupillary block glaucoma
    µ¿°øÂ÷´Ü³ì³»Àå
  • phacolytic glaucoma
    ¼öÁ¤Ã¼¿ëÇØ³ì³»Àå
  • phacomorphic glaucoma
    ¼öÁ¤Ã¼ÆØ´ë³ì³»Àå
  • steroid-induced glaucoma
    ½ºÅ×·ÎÀ̵å³ì³»Àå
  • simple glaucoma
    ´Ü¼ø³ì³»Àå
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • lens-induced glaucoma
    ¼öÁ¤Ã¼³ì³»Àå
  • low-tension glaucoma
    Àú¾È¾Ð³ì³»Àå
  • narrow angle glaucoma
    Á¼Àº¾Õ¹æ°¢³ì³»Àå
  • neovascular glaucoma
    ½Å»ýÇ÷°ü³ì³»Àå
  • normal tension glaucoma
    Á¤»ó¾È¾Ð³ì³»Àå
  • open-angle glaucoma
    °³¹æ°¢³ì³»Àå
  • phacolytic glaucoma
    ¼öÁ¤Ã¼¿ëÇØ³ì³»Àå
  • phacomorphic glaucoma
    ¼öÁ¤Ã¼ÆØ´ë³ì³»Àå
  • pigmentary glaucoma
    »ö¼Ò³ì³»Àå
  • pseudoexfoliation glaucoma
    °ÅÁþºñ´Ã³ì³»Àå
  • pupillary block glaucoma
    µ¿°øÂ÷´Ü³ì³»Àå
  • simple glaucoma
    ´Ü¼ø³ì³»Àå
  • steroid-induced glaucoma
    ½ºÅ×·ÎÀ̵å³ì³»Àå
  • thrombotic glaucoma
    Ç÷Àü³ì³»Àå
  • traumatic glaucoma
    ¿Ü»ó³ì³»Àå
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 12 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • infantile glaucoma
    À¯¾Æ³ì³»Àå.
  • phacolytic glaucoma
    ¼öÁ¤Ã¼¿ëÇØ³ì³»Àå(¡­ÖàÒ®î¡).
  • phacomorphic glaucoma
    ¼öÁ¤Ã¼ÆØ´ë³ì³»Àå
  • pigmentary glaucoma
    »ö¼Ò³ì³»Àå
  • post-irradiation glaucoma
    ¹æ»ç¼±³ì³»Àå
  • primary angle-closure glaucoma
    ¿ø¹ßÆó¼â°¢³ì³»Àå
  • primary glaucoma
    ¿ø¹ß³ì³»Àå(ê«Û¡ÖàÒ®î¡).
  • primary glaucoma ³ª g. primarium
    ¿ø¹ß³ì³»Àå(ê«Û¡ÖàÒ®î¡)
  • primary open-angle glaucoma
    ¿ø¹ß°³¹æ°¢³ì³»Àå
  • prodromal glaucoma
    Àü±¸(±â)³ì³»Àå
  • pupillary block glaucoma
    µ¿°øÂ÷´Ü³ì³»Àå
  • radiation glaucoma
    ¹æ»ç¼±³ì³»Àå
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • enzyme glaucoma
    È¿¼Ò³ì³»Àå
  • exfoliation glaucoma
    ºñ´Ã³ì³»Àå, ³«¼³³ì³»Àå
  • ghost cell glaucoma
    ºó¼¼Æ÷³ì³»Àå, À¯·É¼¼Æ÷³ì³»Àå
  • glaucoma
    ³ì³»Àå(ÖàÒ®î¡).
  • glaucoma implant
    ³ì³»ÀåÀåÄ¡, ³ì³»ÀåÀÓÇöõÆ®
  • glaucoma pannus
    ³ì³»ÀåÆÇ´©½º
  • glaucoma provocative test
    ³ì³»ÀåÀ¯¹ß°Ë»ç
  • glaucoma suspect
    ³ì³»ÀåÀÇÁõ
  • hemolytic glaucoma
    ¿ëÇ÷³ì³»Àå
  • hemorrhagic glaucoma
    ÃâÇ÷³ì³»Àå.
  • hypersecretion glaucoma
    °úºÐºñ³ì³»Àå.
  • imminent angle-closure glaucoma
    Àý¹ÚÆó¼â°¢³ì³»Àå
  • infantile glaucoma
    À¯¾Æ³ì³»Àå.
  • juvenile glaucoma
    ¿¬¼Ò±â³ì³»Àå
  • lens-induced glaucoma
    ¼öÁ¤Ã¼³ì³»Àå
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
GEMSS glaucoma-lens ecopia-microspherophakia-stiffness-shortness syndrome
glc glaucoma
GPOA primary open angle glaucoma
LTG low-tension glaucoma
NAG N-acetyl-D-glucosaminidase; narrow-angle glaucoma; nonagglutinable
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
POAG Primary Open Angle Glaucoma
AACG acute angle closure glaucoma
ACG angle closure glaucoma
COAG chronic open angle glaucoma
HTG high tension glaucoma
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
glaucoma, risk factors If you belong to a high-risk group for glaucoma, have your eyes examined through dilated pupils every 2 years by an eye care professional. High-risk groups include everyone with a family history of glaucoma, everyone over the age of 60 and any Black over the age of 40. (Among Blacks, studies show that glaucoma is: 5 times more likely to occur in Blacks than in Whites and about 4 times more likely to cause blindness in Blacks than in Whites).
(12 Dec 1998)
glaucoma, symptoms at first, there are no symptoms. Vision stays normal, and there is no pain. However, as the disease progress, a person with glaucoma may notice the side vision gradually failing. That is, objects in front may still be seen clearly, but objects to the side may be missed. As the disease worsens, the field of vision narrows and blindness results.
(12 Dec 1998)
glaucoma treatment A laser beam of light is focused on the part of the anterior chamber where the fluid leaves the eye. This results in a series of small changes, which makes it easier for fluid to exit the eye. Over time, the effect of laser surgery may wear off. Patients who have this form of surgery may need to keep taking glaucoma drugs.
Although glaucoma cannot be cured, it can usually be controlled. Medical treatment can be in the form of eyedrops or pills. Some drugs are designed to reduce pressure by slowing the flow of fluid into the eye, while others help to improve fluid drainage. The regular use of medications usually controls the increased fluid pressure. However, these drugs may stop working over time or they may cause side effects so that the eye care professional may select other drugs, change the dose, or use other means to deal with the glaucoma.
Surgery can also help fluid escape from the eye and thereby reduce the pressure. However, surgery is now usually reserved for patients whose pressure cannot be controlled with eyedrops, pills, or laser surgery.
(12 Dec 1998)
phacogenic glaucoma Secondary glaucoma caused by either excessive size or spherical shape of the lens.
Synonym: phacogenic glaucoma.
(05 Mar 2000)
phacolytic glaucoma Glaucoma secondary to hypermature cataract and occlusion of the trabecular drainage meshwork by lens material.
(05 Mar 2000)
phacomorphic glaucoma Secondary glaucoma caused by either excessive size or spherical shape of the lens.
Synonym: phacogenic glaucoma.
(05 Mar 2000)
chronic glaucoma A disorder which is characterised by increased pressure within the eyeball. This occurs secondary to the chronic blockage of normal fluid circulation within the eye. Increased pressure within the eye can cause damage to the optic nerve and eventual blindness. Glaucoma is the leading cause of blindness.
Symptoms include decreased vision, halos around lights (worse at night) and mild chronic headaches. Treatment is generally with beta-blocker eyedrops.
(27 Sep 1997)
closed-angle glaucoma angle-closure glaucoma
pigmentary glaucoma Glaucoma associated with erosion of pigment from the posterior iris, and with an accumulation of pigment particles in the trabecular meshwork.
(05 Mar 2000)
combined glaucoma Glaucoma with angle-closure and open-angle mechanisms in the same eye.
(05 Mar 2000)
compensated glaucoma <ophthalmology> A disorder which is characterised by increased pressure within the eyeball.
This occurs secondary to the chronic blockage of normal fluid circulation within the eye. Increased pressure within the eye can cause damage to the optic nerve and eventual blindness. Glaucoma is the leading cause of blindness.
Symptoms include decreased vision, halos around lights (worse at night) and mild chronic headaches. Treatment is generally with beta-blocker eyedrops.
Synonym: chronic glaucoma, compensated glaucoma, simple glaucoma, glaucoma simplex.
(22 Sep 2002)
congenital glaucoma An affection of infancy, marked by an increase of intraocular pressure with enlargement of the eyeball.
Synonym: congenital glaucoma, hydrophthalmia, hydrophthalmos, hydrophthalmus.
Origin: G. Bous, ox, + ophthalmos, eye
(05 Mar 2000)
corticosteroid-induced glaucoma <ophthalmology> Glaucoma caused by a hereditary predisposition in which local instillation of eyedrops containing corticosteroid causes increased intraocular pressure.
(05 Mar 2000)
haemorrhagic glaucoma Secondary glaucoma after formation of new blood vessels in the iris.
(05 Mar 2000)
pseudoexfoliative capsular glaucoma Secondary glaucoma incident to a degenerative cyclitis producing deposits on anterior lens capsule.
(05 Mar 2000)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á